today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Aldeyra Therapeutics for its resubmission of the New Drug Application (NDA) of reproxalap for the treatment of ...